Trevi Therapeutics
Headquarters country
United States
Registry sponsor category
Industry
- Other names
- Trevi Therapeutics
- Company name
- Trevi Therapeutics
- Organisation type
- Industry
- Registered legal name
- Trevi Therapeutics, Inc.
- US industry code (SIC)
- Pharmaceutical preparations
- Registry sponsor category
- Industry
- Headquarters country
- United States
- Publicly traded (proxy)
- Yes
- Listing at source
- Listed
- SEC filer number (CIK)
- 0001563880
Related records
Trials (17)
- A Food Effect Study to Evaluate the Relative Bioavailability of Nalbuphine Extended-Release Tablets (NAL ER) in Healthy Participants
- A Study of Nalbuphine (Extended Release) ER in Idiopathic Pulmonary Fibrosis (IPF) for Treatment of Cough
- A Study of the Pharmacokinetic Interaction Between Pirfenidone, Nintedanib, and Nalbuphine Extended Release (NAL ER) in Healthy Participants
- Cough Reduction in IPF With Nalbuphine ER
- Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine (NAL) Extended-Release (ER) Tablets
- Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine Extended-Release (NAL ER) Tablets
- NAL ER IPF Respiratory Function and Safety Study
- Open Label Extension Study of Nalbuphine HCl ER in Hemodialysis Patients With Uremic Pruritus
- Open Label Extension Study of Nalbuphine HCl ER in Patients With Prurigo Nodularis
- Oral Abuse Potential Study of Nalbuphine
- Phase 1 Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus
- PRISM Study-Pruritus Relief Through Itch Scratch Modulation
- Refractory Chronic Cough Improvement Via NAL ER (RIVER)
- Study of Nalbuphine ER in Participants With Hepatic Impairment
- Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus
- Study of Nalbuphine HCl ER Tablets in Patients With Prurigo Nodularis
- The Effect of Nalbuphine Extended-Release (NAL ER) on Cough in Participants With Refractory Chronic Cough (RCC)